Foundations of Cancer Therapeutics (FCT) August 14-18, 2023

Home Foundations of Cancer Therapeutics (FCT) August 14-18, 2023

Foundations of Cancer Therapeutics (FCT) August 14-18, 2023

Merck lectures facilitated by Zhiaqiang An

Mon, August 14Tues, August 15Wed, August 16Thurs, August 17Fri, August 18
9:00  Welcome & Introductions CTTP Leadership

9:05 Future of Cancer Therapeutics Development Phil Jones, MD Anderson Institute for Applied Cancer Science (IACS)  
9:40  Course Introduction
Zhiqiang An, UTHealth  

10:00  Part 1 – How New Drugs are Discovered
Target Identification Target Validation  
10:00  Part 2 – Preclinical Studies Formulation activities Drug Metabolism and Pharmakokinetics Nonclinical Safety Assessment  10:00  Part 3 – Testing Individual Drugs in Humans Clinical Development Plan Phase I Trials Phase II Trials         9:00 Radiation Therapy Ahsan Farooqi, MD Anderson  

10:00 Part 4 – Regulatory Review Process Who Regulates? Drug Labeling Global Regulatory Strategy  
9:00 Part 6 – Diversity and Patient Engagement in Clinical Trials   Importance of Patient Diversity in Clinical Trials Patient Engagement in Clinical Trials  

11:00 From Bench to Biotech: (Misad)Ventures of a reformed scientist Sarah Hein, March Biosciences  

11:45 Cancer Drug Development Core Introductions
12-1:30 Lunch & Discussion12-12:45 Lunch & Discussion12-1:30 Lunch & Discussion12-1:30 Lunch & Discussion12-1:30 Lunch & Wrap up
1:30  Part 1 (cont.) Lead Identification Lead Optimization Biologics  

3:00 Overview of Cancer Therapetuics Peter Davies, Texas A&M IBT

3:30 Overview of Cancer Therapeutics Cores Suzanne Tomlinson, GCC
12:45 Small molecule drugs Jin Wang, Baylor College of Medicine  

1:30  Part 2 (cont.) Case study: Antibody Drug Development Zhiqiang An, UTHealth

3:00 Antibody Drug Conjugates to Treat Cancer Zhiqiang An, UTHealth
1:30  Part 3 (cont)
Phase III Trials  

2:30 Peptides and PROTACS Wenshe Liu, Texas A&M  

3:00 Cancer Prevention Strategies Praveen Rajendran, Texas A&M IBT

3:30 Cell Therapy and CAR T-cells Cliona Rooney, Baylor College of Medicine
1:30 (Part 4 cont.) New Drug Application FDA review and Approval Process
Part 5  Postmarketing Studies & Safety Surveillance Phases 3b and 4 Post Market Regulatory Activities